Q-omics provides the consensus-scored UBE2G1 profile across patient tissues and cancer cell-line models. UBE2G1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, UBE2G1 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, UBE2G1 RNA expression shows 19,880 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KICH as cancer lineages where UBE2G1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE2G1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE2G1 survival associations across molecular data types. UBE2G1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE2G1 RNA expression–survival associations across cancer types. High UBE2G1 expression shows unfavorable associations in ACC, MESO, UVM and LUAD, but favorable associations in KIRC and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for UBE2G1 RNA expression.
This table summarizes UBE2G1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for UBE2G1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE2G1 shows lower tumor expression in KICH, COAD and KIRC and higher tumor expression in LUSC, CHOL and LUAD. The KICH box plot shows higher UBE2G1 RNA expression in normal versus tumor tissue (log2 FC = −1.107, t-test p < 0.001).
This table shows molecular features associated with UBE2G1 in patient tissues and cancer cell lines. In patient samples, UBE2G1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, UBE2G1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
